This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

WuXi Biologics Launches US$400 Million Share Buyback Plan

Tipranks - Tipranks - Tue May 26, 7:24PM CDT

Memorial Day Sale – Claim 70% Off TipRanks

Wuxi Biologics (Cayman) ( (HK:2269) ) just unveiled an update.

WuXi Biologics has resolved to activate its shareholder-approved mandate to repurchase shares on the Hong Kong Stock Exchange, authorizing on-market buybacks of up to US$400 million under its existing and future general repurchase mandates. The board believes the current share price undervalues the company’s intrinsic worth and business prospects, and views the program as a signal of confidence in its outlook, while stressing that any buybacks will depend on market conditions and remain entirely at the board’s discretion.

The proposed repurchases, capped by both the 10% mandate limit and the US$400 million budget, are intended to enhance shareholder value without breaching listing, takeover, or Cayman corporate regulations. Management’s move underlines an effort to stabilize the stock and potentially improve capital efficiency, though the company cautions investors that there is no assurance on the timing, size, or execution of any actual share repurchases.

The most recent analyst rating on (HK:2269) stock is a Buy with a HK$50.00 price target. To see the full list of analyst forecasts on Wuxi Biologics (Cayman) stock, see the HK:2269 Stock Forecast page.

More about Wuxi Biologics (Cayman)

WuXi Biologics (Cayman) Inc. is a contract research, development and manufacturing organization serving the global biopharmaceutical industry. The group provides end-to-end biologics services, helping drug developers bring therapies from concept to commercial production, with its shares listed on the Hong Kong Stock Exchange.

Average Trading Volume: 28,969,485

Technical Sentiment Signal: Sell

Current Market Cap: HK$135.5B

For an in-depth examination of 2269 stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Trending Articles

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).